ロード中...
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
BACKGROUND: Pompe disease is a rare, progressive, metabolic disease, and the first treatable inheritable muscle disorder. Enzyme replacement therapy (ERT) with alglucosidase alfa is disease specific and the only medicinal product authorized for the treatment of Pompe disease. Costs of ERT are very h...
保存先:
| 出版年: | Orphanet J Rare Dis |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5729274/ https://ncbi.nlm.nih.gov/pubmed/29237491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0731-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|